NCT05176483: Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are eligible for the dose escalation phase of the study
Exclusions: Patients with prior treatment of XL092, nivolumab, ipilimumab, or agents targeting the IL-2 pathway; Patients with known brain metastasis – see trial for details

Comments are closed.

Up ↑